e-SPACE Heart Failure 2022
Published: 19 October 2022
-
Views:
17616
-
Likes:
7
-
Views:
17616
-
Likes:
7
-
Up Next -
41m 26s
-
53m 32sPart 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2)
-
33m 53s
-
34m 37s
-
1h 2m 37sPart 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs
-
37m 5sPart 1 | Session 12 Meet the expert: Sex differences in advanced heart failure
-
1h 1m 4sPart 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF
-
1h 2m 46sPart 2 | Session 1 Plenary Session 7: New technologies to manage your patients
-
33m 44s
-
1h 4m 11sPart 2 | Session 3 Plenary Session 8: New technologies to treat your patients
-
1h 9sPart 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
-
46m 45s
-
1h 1m 38s
-
30m 11s
-
1h 1m 4sPart 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
-
31m 36s
-
1h 1m 28sPart 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
-
1h 1m 14sPart 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
-
32m 48sPart 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
-
1h 22sPart 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
-
36m 21sPart 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
-
29m 54s
Overview
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day 1
Part 2
Day 2
Faculty Biographies
Philippe Gabriel Steg
Interventional Cardiologist
Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France.
Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.
Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Milton Packer
Distinguished Scholar in Cardiovascular Science
Personal History
Dr Milton Packer was born to Polish immigrants in 1951 and raised in Philadelphia, US. Prior to studying medicine, he was politically active in the 1960s. In his words: “The focus of my upbringing was education, but the major guiding principle in my childhood years (and throughout my entire life) was an uncompromising sense of justice. I was always imbued with the need to strive for and defend the truth.” He began his career in cardiology during a pivotal time for the field, just as interventional cardiology and
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
Cecilia Bahit
Chief of Cardiology
Dr Cecilia Bahit is Chief of Cardiology at INECO Neurociencias Oroño, Santa Fe, AR. She is also currently serving as Co-Chair for the World Stroke Organization Heart & Brain Task Force.
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.